Stock IVVD INVIVYD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-07 EDT 		5-day change 1st Jan Change
2.51 USD +6.36% Intraday chart for Invivyd, Inc. +13.06% -36.29%
04-15 Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda CI
04-12 Invivyd Names Jeremy Gowler as Interim CEO MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
AQ
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
GL
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO
AQ
INVIVYD ANNOUNCES CEO TRANSITION
AQ
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
GL
Invivyd Announces CEO Transition
GL
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
GL
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
GL
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
GL
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
AQ
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
GL
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
AQ
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
GL
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
AQ
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
GL
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
GL
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVVD Stock
  4. News Invivyd, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW